Eli Lilly and Co has announced that it will buy privately held Versanis for potentially up to $1.93bn to strengthen its position in the fast-growing market for weight-loss treatments.
The deal would give it access to Versanis’s drug, bimagrumab, which acts directly on fat cells without reducing appetite and without prompting lean mass loss. These drugs belong to a class of treatments known as incretins that are designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow stomach emptying and decrease appetite.
To find out more, CLICK HERE.
